Journal of Hematology & Thrombosis
Research Article
Survival of Patients with Hematologic Malignancies and Covid-19
Gilberto BL1, Yubelka BM1, Carlos MM1, Humberto CS1, Christian RP1, Francisco ZP1, Estrada Manuel DM1, Marino O1, Efreén M1, Karla R1, Adolfo M2, Irma O2 and Mónica B3
1Department of Hematology, Hospital General de México Dr.
Eduardo Liceaga
2Molecular biology laboratory, Hospital General de México Dr.
Eduardo Liceaga
3Department of Nutrition, Hospital General de México Dr. Eduardo
Liceaga
*Address for Correspondence:
Gilberto BL, Department of Hematology, Hospital General de
México Dr. Eduardo Liceaga Email: domcrupi@gmail.com
Submission: 08 May, 2022
Accepted: 08 June, 2022
Published: 10 June, 2022
Copyright: © 2022 Gilberto BL, et al. This is an open access article
distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Abstract
Purpose: The present study aimed to describe the characteristics
of patients with hematological neoplasms and COVID19, treated in a
reference center in Mexico City, as well as their mortality and the factors
that could influence it.
Patients and methods: This retrospective study included 56 patients
with hematological neoplasms and SARS-CoV-2 infection. The impact
on overall survival (OS) of sex, age, malignancy status, diabetes mellitus,
obesity, overweight, neutrophil count, lymphocyte count, CO-RADS was
evaluated.
Results: Overall mortality was 50%. Univariate analysis identified age
>50 years, history of hypertension, diabetes, and a CO-RADS score >5 as
factors influencing the mortality of patients with hematologic malignancies
and COVID19. Multivariate analysis only identified CO-RADS score > 5.
Conclusion: The mortality of patients with hematological neoplasms
and COVID19 was high in our setting. Frequent co morbidities in our
population can influence mortality.